Great talk by @MdArpita #ucsf at #IKCSNA25 succinctly summarizing options in the challenging setting of IO resistance in RCC. We are looking ahead to earlier implementation of HIF2a blockade and earlier access to trials for our patients. @KidneyCancer
Kelly Fitzgerald
@KellyNFitz
GU oncology at UCSF | MSKCC fellowship alum | cancer immunology and metabolism | tweets are mine
130 Following 269 Followers 68 Posts
Latest posts 5
@BraunMDPhD eloquently summarizes the principles driving innovation in immunotherapy at #KCRS24
View quoted post on X
Interesting to consider a ‘very favorable risk’ subgroup of ccRCC patients and the role of VEGFR targeted therapies here. How will HIF2a blockade perform in these patients?
#MartinZarba @DrDanielHeng @UCalgaryMed with IMDC very/favorable risk #kidneycancer — all regimens w excellent survival. Ipi-nivo doublet falls short in very favorable risk RCC. @ASCO #ASCO24 @OncoAlertView quoted post on X
Congrats to @dsahil320 Sahil Doshi for this retrospective analysis of outcomes on first-line therapy in >100 patients with #chromophobe rcc. Looking forward to seeing longer term follow-up in patients in the doublet cohorts. @MVossMD @NazliDizman @OncHahn @dreaknezevic
Happy to share our findings at #IKCSNA23! In our single-institution retrospective cohort, no evidence of superiority of either IO/IO or TKI/IO in #kidneycancer 1L tx with regard to PFS2, including in groups w/ sarcomatoid features, BAP1 mutation, or deep RECIST response.